ESAB Corp 10-Q

Item 1. Financial Statements ESAB CORPORATION CONSOLIDATED AND CONDENSED STATEMENTS OF OPERATIONS Dollars in thousands, except per share amounts (Unaudited) Three Months Ended Nine Months Ended October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 Net sales $ 727,845 $ 673,250 $ 2,121,569 $ 2,070,047 Cost of sales 458,545 419,460 1,331,020 1,290,915 Gross profit 269,300 253,790 790,549 779,132 Selling, general and administrative expense 158,335 145,900 454,756 434,537 Restructuring and other related charges 4,347 1,875 10,236 8,572 Operating income 106,618 106,015 325,557 336,023 Pension settlement loss — — — 12,155 Interest expense and other, net 23,584 16,894 61,365 49,925 Income from continuing operations before income taxes 83,034 89,121 264,192 273,943 Income tax expense 17,694 18,074 56,476 54,463 Net income from continuing operations 65,340 71,047 207,716 219,480 Loss from discontinued operations, net of taxes ( 8,819 ) ( 1,214 ) ( 13,259 ) ( 3,684 ) Net income 56,521 69,833 194,457 215,796 Income attributable to noncontrolling interest, net of taxes ( 1,674 ) ( 1,593 ) ( 5,364 ) ( 4,698 ) Net income attributable to ESAB Corporation $ 54,847 $ 68,240 $ 189,093 $ 211,098 Earnings (loss) per share – basic Income from continuing operations $ 1.05 $ 1.14 $ 3.33 $ 3.54 Loss on discontinued operations ( 0.15 ) ( 0.02 ) ( 0.22 ) ( 0.06 ) Net income per share – basic $ 0.90 $ 1.12 $ 3.11 $ 3.48 Earnings (loss) per share – diluted Income from continuing operations $ 1.04 $ 1.13 $ 3.29 $ 3.50 Loss on discontinued operations ( 0.14 ) ( 0.02 ) ( 0.22 ) ( 0.06 ) Net income per share – diluted $ 0.90 $ 1.11 $ 3.07 $ 3.44 See Notes to Consolidated and Condensed Financial Statements. 2 ESAB CORPORATION CONSOLIDATED AND CONDENSED STATEMENTS OF COMPREHENSIVE INCOME Dollars in thousands (Unaudited) Three Months Ended Nine Months Ended October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 Net income $ 56,521 $ 69,833 $ 194,457 $ 215,796 Other comprehensive (loss) income: Foreign currency translation, net of tax expense (benefit) of $ 947 , $( 2,871 ), $( 10,625 ) and $( 924 ) ( 6,087 ) 63,675 175,461 23,764 Unrealized loss on derivatives designated and qualifying as cash flow hedges, net of tax benefit of $ — , $( 911 ), $( 497 ) and $( 1,155 ) — ( 3,130 ) ( 1,816 ) ( 3,968 ) Defined benefit pension and other post-retirement plan activity, net of tax expense of $ 50 , $ 23 , $ 158 and $ 270 250 343 773 1,299 Other comprehensive (loss) income ( 5,837 ) 60,888 174,418 21,095 Comprehensive income 50,684 130,721 368,875 236,891 Comprehensive income attributable to noncontrolling interest ( 348 ) ( 2,302 ) ( 4,418 ) ( 4,715 ) Comprehensive income attributable to ESAB Corporation $ 50,336 $ 128,419 $ 364,457 $ 232,176 See Notes to Consolidated and Condensed Financial Statements. 3 ESAB CORPORATION CONSOLIDATED AND CONDENSED BALANCE SHEETS Dollars in thousands, except share and per share amounts (Unaudited) October 3, 2025 December 31, 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 218,219 $ 249,358 Trade receivables, less allowance for credit losses of $ 23,557 and $ 23,850 460,469 370,321 Inventories, net 503,722 403,711 Prepaid expenses 64,291 55,665 Other current assets 87,020 69,327 Total current assets 1,333,721 1,148,382 Property, plant and equipment, net 357,927 298,347 Goodwill 1,962,752 1,651,993 Intangible assets, net 684,439 487,993 Lease assets - right of use 133,751 89,859 Other assets 396,813 357,401 Total assets 4,869,403 4,033,975 LIABILITIES AND EQUITY CURRENT LIABILITIES: Current portion of debt 2,175 15,000 Accounts payable 342,214 318,493 Accrued liabilities 324,685 298,558 Total current liabilities 669,074 632,051 Long-term debt 1,334,123 1,060,739 Other liabilities 704,179 532,936 Total liabilities 2,707,376 2,225,726 Equity: Common stock - $ 0.001 par value - 600,000,000 shares authorized, 60,709,740 and 60,517,574 shares outstanding as of October 3, 2025 and December 31, 2024, respectively 61 61 Additional paid-in capital 1,900,871 1,901,337 Retained earnings 769,226 597,180 Accumulated other comprehensive loss ( 554,210 ) ( 729,574 ) Total ESAB Corporation equity 2,115,948 1,769,004 Noncontrolling interest 46,079 39,245 Total equity 2,162,027 1,808,249 Total liabilities and equity $ 4,869,403 $ 4,033,975 See Notes to Consolidated and Condensed Financial Statements. 4 ESAB CORPORATION CONSOLIDATED AND CONDENSED STATEMENTS OF EQUITY Dollars in thousands, except share and per share amounts (Unaudited) Common Stock Additional Paid-in Capital Retained Earnings Accumulated Other Comprehensive Loss Noncontrolling Interest Total Shares Amount Balance at December 31, 2024 60,517,574 $ 61 $ 1,901,337 $ 597,180 $ ( 729,574 ) $ 39,245 $ 1,808,249 Net income — — — 67,363 — 2,469 69,832 Dividends declared ($ 0.08 per share) — — — ( 4,868 ) — — ( 4,868 ) Distributions to noncontrolling owners — — — — — ( 1,168 ) ( 1,168 ) Other comprehensive income, net of tax benefit of $ 4,808 — — — — 77,717 118 77,835 Common stock-based award activity 105,162 — 512 — — — 512 Balance at April 4, 2025 60,622,736 61 1,901,849 659,675 ( 651,857 ) 40,664 1,950,392 Net income — — — 66,883 — 1,221 68,104 Dividends declared ($ 0.10 per share) — — — ( 6,091 ) — — ( 6,091 ) Distributions to noncontrolling owners — — — — — ( 6 ) ( 6 ) Other comprehensive income, net of tax benefit of $ 7,153 — — — — 102,158 262 102,420 Common stock-based award activity 74,050 — ( 3,048 ) — — — ( 3,048 ) Balance at July 4, 2025 60,696,786 61 1,898,801 720,467 ( 549,699 ) 42,141 2,111,771 Net income — — — 54,847 — 1,674 56,521 Dividends declared ($ 0.10 per share) — — — ( 6,088 ) — — ( 6,088 ) Distributions and purchases relating to noncontrolling owners — — — — — 3,590 3,590 Other comprehensive income, net of tax expense of $ 997 — — — — ( 4,511 ) ( 1,326 ) ( 5,837 ) Common stock-based award activity 12,954 — 2,070 — — — 2,070 Balance at October 3, 2025 60,709,740 $ 61 $ 1,900,871 $ 769,226 $ ( 554,210 ) $ 46,079 $ 2,162,027 5 Common Stock Additional Paid-in Capital Retained Earnings Accumulated Other Comprehensive Loss Noncontrolling Interest Total Shares Amount Balance at December 31, 2023 60,295,634 $ 60 $ 1,881,054 $ 350,557 $ ( 624,272 ) $ 40,258 $ 1,647,657 Net income — — — 59,951 — 1,643 61,594 Dividends declared ($ 0.06 per share) — — — ( 3,641 ) — — ( 3,641 ) Other comprehensive loss, net of tax expense of $ 2,029 — — — — ( 23,389 ) ( 323 ) ( 23,712 ) Common stock-based award activity 128,787 — 480 — — — 480 Balance at March 29, 2024 60,424,421 60 1,881,534 406,867 ( 647,661 ) 41,578 1,682,378 Net income — — — 82,907 — 1,462 84,369 Dividends declared ($ 0.08 per share) — — — ( 4,856 ) — — ( 4,856 ) Distributions to noncontrolling owners — — — — — ( 1,218 ) ( 1,218 ) Other comprehensive loss, net of tax benefit of $ 79 — — — — ( 15,712 ) ( 369 ) ( 16,081 ) Common stock-based award activity 14,417 — 4,833 — — — 4,833 Balance at June 28, 2024 60,438,838 60 1,886,367 484,918 ( 663,373 ) 41,453 1,749,425 Net income — — — 68,240 — 1,593 69,833 Dividends declared ($ 0.08 per share) — — — ( 4,858 ) — — ( 4,858 ) Distributions to noncontrolling owners — — 2,860 — ( 1,706 ) ( 3,155 ) ( 2,001 ) Other comprehensive loss, net of tax benefit of $ 3,759 — — — — 60,179 709 60,888 Common stock-based award activity 5,408 — 4,438 — — — 4,438 Balance at September 27, 2024 60,444,246 $ 60 $ 1,893,665 $ 548,300 $ ( 604,900 ) $ 40,600 $ 1,877,725 See Notes to Consolidated and Condensed Financial Statements. 6 ESAB CORPORATION CONSOLIDATED AND CONDENSED STATEMENTS OF CASH FLOWS Dollars in thousands (Unaudited) Nine Months Ended October 3, 2025 September 27, 2024 Cash flows from operating activities: Net income $ 194,457 $ 215,796 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation, amortization and other impairment charges 58,731 50,028 Net gain on sale of property, plant and equipment ( 5,697 ) ( 1,060 ) Stock-based compensation expense 12,542 14,473 Deferred income tax (benefit) expense ( 7,707 ) 2,394 Non-cash interest expense 1,882 2,259 Pension settlement loss — 12,155 Changes in operating assets and liabilities: Trade receivables, net ( 50,381 ) ( 39,075 ) Inventories, net ( 28,924 ) ( 31,651 ) Accounts payable ( 9,893 ) 16,895 Other operating assets and liabilities ( 1,496 ) ( 13,691 ) Net cash provided by operating activities 163,514 228,523 Cash flows from investing activities: Purchases of property, plant and equipment ( 27,654 ) ( 27,071 ) Proceeds from sale of property, plant and equipment 4,731 3,452 Acquisitions, net of cash received ( 439,669 ) ( 86,537 ) Other investing 539 ( 4,058 ) Net cash used in investing activities ( 462,053 ) ( 114,214 ) Cash flows from financing activities: Proceeds from borrowings on Senior Notes — 700,000 Proceeds from borrowings on revolving credit facilities and other 359,591 205,000 Repayments of borrowings on Term Loans ( 10,000 ) ( 597,500 ) Repayments of borrowings on revolving credit facilities and other ( 90,442 ) ( 236,623 ) Payment of debt issuance costs — ( 10,423 ) Payment of dividends ( 15,821 ) ( 12,135 ) Distributions to noncontrolling interest holders ( 3,057 ) ( 2,644 ) Other financing ( 13,008 ) ( 5,099 ) Net cash provided by financing activities 227,263 40,576 Effect of foreign exchange rates on Cash and cash equivalents 40,137 ( 3,218 ) (Decrease) increase in Cash and cash equivalents ( 31,139 ) 151,667 Cash and cash equivalents, beginning of period 249,358 102,003 Cash and cash equivalents, end of period $ 218,219 $ 253,670 See Notes to Consolidated and Condensed Financial Statements. 7 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) 1. Organization and Basis of Presentation Founded in 1904, ESAB Corporation (“ESAB” or the “Company”) is a focused premier industrial compounder. ESAB provides its partners with fabrication technology advanced equipment, consumables, gas control equipment, robotics and digital solutions. The Company’s rich history of innovative products, workflow solutions and its business management system, ESAB Business Excellence (“EBX”), enables the Company’s purpose of Shaping the world we imagine TM . The Company’s products are utilized to solve challenges in a wide range of industries, including cutting, joining and automated welding and gas control. The Company conducts its operations through two reportable segments. These segments consist of the “Americas,” which includes operations in North America and South America, and “EMEA & APAC,” which includes Europe, Middle East, India, Africa and Asia Pacific. The Company’s fiscal year ends December 31. The Company’s third quarter ends on the last business day of the 13 th complete week after the end of the prior quarter. As used herein, the third quarter results for 2025 and 2024 refer to the 13-week periods ended October 3, 2025 and September 27, 2024, respectively. Russia and Ukraine Conflict The invasion of Ukraine by Russia and the sanctions imposed in response have increased the level of economic and political uncertainty. While ESAB continues to closely monitor the situation and evaluate options, the Company is meeting current contractual obligations while addressing applicable laws and regulations. For the three and nine months ended October 3, 2025, Russia represented approximately 6 % and 5 %, respectively, of the Company’s Net sales and approximately $ 3 million and $ 9 million, respectively, of its Net income. Russia also has approximately 5 % of the Company’s total net assets as of October 3, 2025, including approximately $ 48 million of Cash and cash equivalents that may be subject to delays in withdrawing from Russia, based upon the current environment at that time. In case of the disposition of the Russia business, a portion of goodwill would need to be allocated and disposed of at the relative fair value attributable to the Russia business. Russia has a cumulative translation loss of approximately $ 110 million as of October 3, 2025, which would be realized upon a transition out. The Company is closely monitoring developments in Ukraine and Russia. Changes in laws and regulations or other factors impacting the Company’s ability to fulfill contractual obligations could have an adverse effect on the results of operations and cash flows. Basis of Presentation The Consolidated and Condensed Financial Statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with the accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated and Condensed Financial Statements reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. Intercompany transactions and accounts are eliminated in consolidation. Certain line items on our Consolidated and Condensed Statements of Cash Flows have been reclassified to conform to the current presentation. In the normal course of business, the Company incurs research and development costs related to new product development, which are expensed as incurred and included in Selling, general and administrative expense on the Company’s Consolidated and Condensed Statements of Operations. Research and development costs were $ 10.5 million and $ 31.1 million during the three and nine months ended October 3, 2025, respectively, and $ 9.2 million and $ 29.0 million for the three and nine months ended September 27, 2024, respectively. T hese amounts do not include development and application engineering costs incurred in conjunction with fulfilling customer orders and executing customer projects, nor do they include costs related to securing third party product rights. The Company expects to continue making significant expenditures for research and development to maintain and improve its competitive positions. The accompanying interim Consolidated and Condensed Financial Statements and the related notes should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”), filed with the SEC on February 20, 2025. 8 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) 2. Discontinued Operations The Company holds certain asbestos-related contingencies and insurance coverages from divested businesses for which it does not have an interest in the ongoing operations. The Company has classified asbestos-related activity included in its Consolidated and Condensed Statements of Operations as part of Loss from discontinued operations, net of taxes. This activity consists primarily of expected settlements, legal and administrative expenses associated with the above liabilities. Discontinued operations consist primarily of Selling, general and administrative expense, with an associated tax impact that is considered immaterial. See Note 14, “Commitments and Contingencies” for further information. Cas h used in operating activities related to discontinued operations was $ 3.6 million and $ 10.8 million for the three and nine months ended October 3, 2025, respectively, and $ 3.6 million and $ 12.1 million for the three and nine months ended September 27, 2024, respectively . 3. Acquisitions The Company continually evaluates potential acquisitions that either strategically fit with its existing portfolio or expand its portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for using the acquisition method and have resulted in the recognition of goodwill in the Company’s financial statements. This goodwill arises because the purchase prices for these businesses exceeded the fair value of acquired identifiable net assets. This excess is attributable to a variety of factors, including, but not limited to, the anticipated future earnings and cash flow potential of the acquired businesses; prevailing market multiples applied to earnings and cash flows in comparable transactions; the competitive nature of the acquisition processes; the strategic benefits of accelerating market entry or enhancing existing product offerings without incurring the time, cost and risk associated with internal development; and the complementary fit and expected synergies these businesses contribute to the Company’s existing operations. Under the acquisition method of accounting, the Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities from information obtained during due diligence and through other sources. As the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, the Company is able to refine the estimates of fair value and more accurately allocate the purchase price. The fair values of acquired intangibles are determined based on estimates and assumptions that form the basis of the forecasted results of the acquired business including earnings before interest, taxes, depreciation and amortization (“EBITDA”), revenue, revenue growth rates, royalty rates and customer attrition rates. These assumptions are forward looking and could be affected by future economic and market conditions. The Company engages third-party valuation specialists who provide guidance on the Company’s critical assumptions and calculations of the fair value of acquired intangible assets in connection with significant acquisitions. The Company makes appropriate adjustments to purchase price allocations prior to completion of the applicable measurement period, as required. Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment. The following table describes the Company’s 2025 acquisition activity, for which it acquired 100% of the equity and voting interest of each acquired entity. Acquisition Date Company Description Segment April 30, 2025 Bavaria Schweisstechnik (“Bavaria”) A European provider of submerged-arc welding applications EMEA & APAC June 4, 2025 DeltaP s.r.l. (“DeltaP”) A European provider of medical central gas systems and aftermarket services EMEA & APAC July 9, 2025 Aktiv Technologies Private Limited (“Aktiv”) An industrial gas equipment manufacturer based in India EMEA & APAC August 22, 2025 EWM GmbH (“EWM”) A Global leader in heavy industrial welding equipment and advanced automation EMEA & APAC The following table summarizes the preliminary allocation of the purchase price to the assets acquired and liabilities assumed for the nine months ended October 3, 2025. These amounts, including inventories, deferred taxes, intangible assets, and property, plant and equipment, are determined based upon certain valuations and studies that have yet to be finalized. Accordingly, the assets acquired and liabilities assumed, as detailed below, are subject to adjustment once the detailed analyses are completed. None of the goodwill is expected to be deductible for tax purposes. 9 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) EWM All Others Total (in thousands) Cash and cash equivalents $ 10,349 $ 6,803 $ 17,152 Inventories, net 39,903 7,662 47,565 Property, plant and equipment, net 31,470 6,284 37,754 Goodwill (1) 162,926 65,865 228,791 Identifiable intangible assets (2) 137,141 43,938 181,079 Customer relationships (3) 96,433 35,771 132,204 Trade names 20,536 6,294 26,830 Technology 20,172 1,873 22,045 Deferred tax liability ( 35,605 ) ( 12,006 ) ( 47,611 ) Other, net (4) ( 11,438 ) ( 890 ) ( 12,328 ) Preliminary purchase price consideration 334,746 117,656 452,402 (1) Goodwill for “All Others” includes approximately $ 39 million for Bavaria and $ 17 million for Aktiv. (2) Definite-lived intangibles are subject to estimated weighted-average useful lives ranging from five to twenty years . (3) Customer relationships for “All Others” includes approximately $ 23 million for Bavaria. (4) Includes current and non-current amounts and non-controlling interest. For the three and nine months ended October 3, 2025, the above acquisitions added approximately $ 27 million and $ 35 million, respectively, to Net sales. The Company incurred approximately $ 1 million and $ 10 million of acquisition-related costs for the acquisitions completed in 2025 in the three and nine months ended October 3, 2025, respectively. These costs were expensed in Selling, general and administrative expense in the Consolidated and Condensed Statements of Operations. For a description of the Company’s acquisition activity for the year ended December 31, 2024, reference is made to the financial statements as of and for the year ended December 31, 2024 and Note 5, “Acquisitions” thereto in the Company’s 2024 Annual Report. 4. Revenue The Company provides fabrication technology advanced equipment, consumables, gas control equipment, robotics and digital solutions. Substantially all revenue is recognized at a point in time. The Company disaggregates its revenue into the following product groups: Three Months Ended Nine Months Ended October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 (in thousands) Equipment $ 249,948 $ 219,415 $ 714,375 $ 665,934 Consumables 477,897 453,835 1,407,194 1,404,113 $ 727,845 $ 673,250 $ 2,121,569 $ 2,070,047 The sales mix in the above table is relatively consistent across both reportable segments. The consumables product grouping generally has less production complexity and shorter production cycles than equipment products. Given the nature of the business, the total amount of unsatisfied performance obligations with an original contract duration of greater than one year as of October 3, 2025 is immaterial. In some circumstances, customers are billed in advance of revenue recognition, resulting in contract liabilities. As of December 31, 2024 and December 31, 2023, total contract liabilities were $ 26.4 million and $ 31.2 million, respectively, and were included in Accrued liabilities on the Consolidated and Condensed Balance Sheets. During the three and nine months ended October 3, 2025, revenue recognized that was included in the contract liabilities balance at the beginning of the year was $ 1.9 million and $ 15.5 million, respectively. During the three and nine months ended September 27, 2024, revenue recognized that was included in the contract liabilities balance at the beginning of the year was $ 1.3 million and $ 22.6 million, respectively. As of October 3, 2025 and September 27, 2024, total contract liabilities were $ 27.2 million and $ 27.8 million, respectively. 10 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) Allowance for Credit Losses A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Consolidated and Condensed Balance Sheets is as follows: Nine Months Ended October 3, 2025 Balance at Beginning of Period Charged to Expense, net Write-Offs and Deductions Foreign Currency Translation Balance at End of Period (In thousands) Allowance for credit losses $ 23,850 $ 1,138 $ ( 2,871 ) $ 1,440 $ 23,557 5. Earnings per Share from Continuing Operations The Company has unvested share-based payment awards with a right to receive non-forfeitable dividends, which are considered participating securities. The Company allocates earnings to participating securities and computed earnings per share using the two-class method as follows: Three Months Ended Nine Months Ended October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 (In thousands, except share and per share data) Computation of earnings per share from continuing operations – basic: Income from continuing operations attributable to ESAB Corporation (1) $ 63,666 $ 69,454 $ 202,352 $ 214,782 Distributed and undistributed earnings allocated to nonvested shares ( 131 ) ( 305 ) ( 546 ) ( 1,052 ) Income from continuing operations attributable to common stockholders $ 63,535 $ 69,149 $ 201,806 $ 213,730 Weighted-average shares of Common stock outstanding – basic 60,703,560 60,439,818 60,668,678 60,406,056 Income per share from continuing operations – basic $ 1.05 $ 1.14 $ 3.33 $ 3.54 Computation of earnings per share from continuing operations – diluted: Income from continuing operations attributable to common stockholders $ 63,535 $ 69,149 $ 201,806 $ 213,730 Weighted-average shares of Common stock outstanding – basic 60,703,560 60,439,818 60,668,678 60,406,056 Net effect of potentially dilutive securities (2) 534,781 646,311 608,723 644,791 Weighted-average shares of Common stock outstanding – dilution 61,238,341 61,086,129 61,277,401 61,050,847 Net income per share from continuing operations – diluted $ 1.04 $ 1.13 $ 3.29 $ 3.50 (1) Net income from continuing operations attributable to ESAB Corporation for the respective periods is calculated using Net income from continuing operations, less Income attributable to noncontrolling interest, net of taxes, of $ 1.7 million and $ 5.4 million for the three and nine months ended October 3, 2025, respectively, and $ 1.6 million and $ 4.7 million for the three and nine months ended September 27, 2024, respectively. (2) Potentially dilutive securities include stock options, performance-based restricted stock units and non-performance-based restricted stock units. 6. Income Taxes During the three and nine months ended October 3, 2025, Income from continuing operations before income taxes was $ 83.0 million and $ 264.2 million, respectively, while Income tax expense was $ 17.7 million and $ 56.5 million, respectively. The effective tax rate was 21.3 % and 21.4 % for the three and nine months ended October 3, 2025, respectively. The effective tax rate differed from the 2025 U.S. federal statutory rate of 21.0% primarily due to the impact of a law change in a foreign jurisdiction and withholding tax offset by a release of a valuation allowance in a foreign jurisdiction. During the three and nine months ended September 27, 2024, Income from continuing operations before income taxes was $ 89.1 million and $ 273.9 million, respectively, while Income tax expense was $ 18.1 million and $ 54.5 million, respectively. The effective tax rate was 20.3 % and 19.9 % for the three and nine months ended September 27, 2024, respectively. The 11 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) effective tax rate differed from the 2024 U.S. federal statutory rate of 21.0% primarily due to a favorable final ruling in a tax case in a foreign jurisdiction and an agreement with a taxing authority on the treatment of subsidy income in a foreign jurisdiction. 7. Inventories, Net Inventories, net consisted of the following: October 3, 2025 December 31, 2024 (In thousands) Raw materials $ 171,915 $ 151,248 Work in process 51,161 41,698 Finished goods 321,539 251,994 544,615 444,940 Allowance for excess, slow-moving and obsolete inventory ( 40,893 ) ( 41,229 ) $ 503,722 $ 403,711 8. Accrued and Other Liabilities Accrued and Other liabilities in the Consolidated and Condensed Balance Sheets consisted of the following: October 3, 2025 December 31, 2024 Current Noncurrent Current Noncurrent (In thousands) Accrued taxes and deferred tax liabilities $ 54,338 $ 199,396 $ 46,395 $ 151,642 Compensation and related benefits 82,674 53,244 80,451 48,350 Asbestos liability 43,335 279,473 40,779 253,287 Contract liabilities 27,244 — 26,390 — Lease liabilities 22,569 108,171 21,459 66,042 Warranty liability 13,325 — 12,794 — Third-party commissions 16,109 — 17,346 — Restructuring liability 6,994 27 4,732 374 Accrued interest 18,966 — 8,077 — Other 39,131 63,868 40,135 13,241 $ 324,685 $ 704,179 $ 298,558 $ 532,936 Accrued Warranty Liability A summary of the activity in the Company’s warranty liability included in Accrued liabilities in the Company’s Consolidated and Condensed Balance Sheets is as follows: Nine Months Ended October 3, 2025 September 27, 2024 (In thousands) Warranty liability, beginning of period $ 12,794 $ 12,606 Accrued warranty expense 6,526 8,026 Changes in estimates related to pre-existing warranties 906 1,829 Cost of warranty service work performed ( 9,102 ) ( 8,507 ) Foreign exchange translation effect and other 2,201 ( 40 ) Warranty liability, end of period $ 13,325 $ 13,914 12 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) Accrued Restructuring Liability The Company’s restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company’s restructuring liability included in Accrued liabilities and Other liabilities in the Consolidated and Condensed Balance Sheets is as follows: Nine Months Ended October 3, 2025 Balance at Beginning of Period Charges Payments Foreign Currency Translation Balance at End of Period (In thousands) Termination benefits (1) $ 3,845 $ 7,089 $ ( 5,240 ) $ 703 $ 6,397 Facility closure costs and other (2) 1,261 3,147 ( 3,593 ) ( 191 ) 624 $ 5,106 $ 10,236 $ ( 8,833 ) $ 512 $ 7,021 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment and other costs in connection with the closure and optimization of facilities and product lines. 9. Benefit Plans The Company sponsors various defined benefit plans and other post-retirement benefits plans, including health and life insurance, for certain eligible employees or former employees. During the nine months ended September 27, 2024, the Company recognized a non-cash pension settlement loss of $ 12.2 million related to the transfer of plan assets to a third party as part of externalizing the risk associated with a foreign defined benefit plan. This amount is reflected in Pension settlement loss in the Consolidated and Condensed Statements of Operations. 10. Debt The following table shows the components of the Company’s debt: October 3, 2025 December 31, 2024 (In thousands) Term loans $ 375,000 $ 385,000 Senior unsecured notes 700,000 700,000 Revolving credit facility 260,000 — Other debt 8,888 — Total debt 1,343,888 1,085,000 Current portion of debt ( 2,175 ) ( 15,000 ) Unamortized deferred financing fees ( 7,590 ) ( 9,261 ) Long-term debt $ 1,334,123 $ 1,060,739 Senior Notes, Term Loans and Revolving Credit Facility On April 4, 2022, the Company entered into a credit agreement (as amended and restated from time-to-time, the “Credit Agreement”) that initially consisted of a $ 750 million revolving credit facility (the “Revolving Facility”) with a maturity date of April 4, 2027, a Term A-1 loan with an initial aggregate principal amount of $ 400 million (the “Term Loan A-1 Facility”), with a maturity date of April 4, 2027; and a $ 600 million 364 -day senior term loan facility (the “Term Loan A-2 Facility”) with a maturity date of April 3, 2023. The Revolving Facility contains a $ 300 million foreign currency sublimit and a $ 50 million swing line loan sub-facility. On June 28, 2022, the Company amended and restated the Credit Agreement by entering into Amendment No. 2 to the Credit Agreement (“Credit Agreement Amendment”). The Credit Agreement Amendment provides for a $ 600 million term loan facility (the “Term Loan A-3 Facility,” collectively the “Term Facilities” with Term A-1 Facility and Term A-2 Facility) with a maturity date of April 3, 2025 to refinance the Company’s existing Term Loan A-2 Facility. Also on June 28, 2022, the 13 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) Company borrowed the entire $ 600 million under Term Loan A-3 Facility to fund the repayment of the Term Loan A-2 Facility. On April 9, 2024, the Company issued $ 700 million in aggregate principal amount of 6.25 % senior notes due 2029 (the “Senior Notes”) governed by an indenture (the “Indenture”). The Company used the net proceeds from the Senior Notes to pay off its Term Loan A-3 Facility and pay fees associated with the offering. After the quarter ended October 3, 2025, on October 16, 2025, the Company entered into an Amended and Restated Credit Agreement that, among other things, provides for (i) a senior term loan A facility in an aggregate principal amount of $ 350 million, and (ii) a senior revolving credit facility in the amount of $ 1.05 billion to replace the Company’s existing $ 400 million Term Loan A-1 Facility and $ 750 million Revolving Facility and pay off the outstanding principal and interest thereunder. Both facilities mature on October 16, 2030, subject to a springing maturity date under certain circumstances. The new covenants and applicable interest rate under the Amended and Restated Credit Agreement are substantially similar to the prior agreement. Refer to “Note 16, Subsequent Events” for further details. As of October 3, 2025, the Company’s debt primarily consisted of the following facilities: • A $ 750 million Revolving Facility with a maturity date of April 4, 2027, with $ 260 million drawn; • A Term Loan A-1 Facility with an aggregate principal amount of $ 375 million and a maturity date of April 4, 2027; and • Senior Notes with an aggregate principal amount of $ 700 million and a maturity date of April 15, 2029. The Credit Agreement and the Indenture contain customary covenants. These covenants limit the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments or pay dividends. In addition, the Credit Agreement requires that the Company maintains certain financial covenants and the Company was in compliance with all of its debt covenants as of October 3, 2025. The Credit Agreement and the Indenture contain various events of default (including failure to comply with the covenants under the Credit Agreement and related agreements) and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Term A-1 Facility, Senior Notes and the Revolving Facility. Certain United States subsidiaries of the Company have agreed to guarantee the obligations of the Company under the Credit Agreement and Senior Notes. Loans made under the Term A-1 Facility will bear interest, at the election of the Company, at either the base rate (as defined in the Credit Agreement) or at the term Secured Overnight Financing Rate (“SOFR”) plus an adjustment (as defined in the Credit Agreement), in each case, plus the applicable interest rate margin. Loans made under the Revolving Facility will bear interest, at the election of the Company, at either the base rate or, (i) in the case of loans denominated in dollars, the term SOFR plus an adjustment or the daily simple SOFR plus an adjustment, (ii) in the case of loans denominated in euros, the adjusted Euro Interbank Offered Rate (“EURIBOR”) rate and, (iii) in the case of loans denominated in sterling, Sterling Overnight Index Average (“SONIA”) plus an adjustment (as all such rates are defined in the Credit Agreement Amendment), in each case, plus the applicable interest rate margin. The applicable interest rate margin changes based upon the Company’s total leverage ratio (consolidated total debt divided by EBITDA, as defined in the credit agreement and ranging from 1.125 % to 1.750 % or in the case of the base rate margin, 0.125 % to 0.750 %). Each swing line loan denominated in dollars will bear interest at the base rate plus the applicable interest rate margin. To manage exposures to currency exchange rates and interest rates arising in Long-term debt, the Company entered into interest rate and cross-currency swap agreements. Refer to Note 11, “Derivatives” for additional information. As of October 3, 2025, the weighted-average interest rate of borrowings under the Credit Agreement and Indenture was 5.55 %, including the net impact from the cross-currency swaps and excluding accretion of deferred financing fees, and there was $ 490 million of borrowing capacity available under the Revolving Facility, subject to the Company meeting financial covenants and other requirements. 14 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) Other Indebtedness In addition to the debt agreements discussed above, the Company also has the ability to incur approximately $ 50 million of indebtedness pursuant to certain uncommitted credit lines, consisting of an uncommitted credit line that the Company has used from time to time in the past for short-term working capital needs. The Company is party to letter of credit facilities with an aggregate capacity of $ 113.3 million. Total letters of credit of $ 32.4 million were outstanding as of October 3, 2025. Deferred Financing Fees The Company had total deferred financing fees of $ 8.0 million included in its Consolidated and Condensed Balance Sheets as of October 3, 2025, which will be charged to Interest expense and other, net, over the term of the related debt instruments. The costs associated with the Term Facilities and Senior Notes noted above will be amortized over the contractual term of the related facility and the costs associated with these will be amortized over the life of the Credit Agreement or the Indenture. Of the $ 8.0 million, $ 0.4 million of deferred financing fees relating to the Revolving Facility are included in Other assets and $ 7.6 million of deferred financing fees relating to the Term Facilities and Senior Notes are recorded as a contra-liability within Long-term debt. 11. Derivatives The Company uses derivative instruments to manage exposures to currency exchange rates and interest rates arising in connection with long-term debt and the normal course of business. The Company has established policies and procedures that govern the risk management of these exposures. Both at inception and on an ongoing basis, the derivative instruments that qualify for hedge accounting are assessed as to their effectiveness, when applicable. The Company is subject to the credit risk of counterparties to derivative instruments. Counterparties include a number of major banks and financial institutions. None of the concentrations of risk with an individual counterparty was considered significant as of October 3, 2025. The Company does not expect any counterparties to fail to meet their obligations. The Company records derivatives in the Consolidated and Condensed Balance Sheets at fair value. Cash Flow Hedges On July 14, 2022, the Company entered into two interest rate swap agreements to manage interest rate risk exposure. The aggregate notional amount of these contracts was $ 600 million and they were set to mature in April 2025. These interest rate swap agreements utilized by the Company effectively modify the Company’s exposure to interest rate risk by converting a portion of the Company’s floating-rate debt to a fixed rate of 3.293 %, plus a spread, thus reducing the impact of interest-rate changes on future interest expense. The applicable spread may vary between 1.125 % to 1.750 %, depending on the total leverage ratio of the Company. In March 2024, the Company settled one of the interest rate swaps associated with the Company’s floating-rate debt and received $ 5.5 million in connection with that settlement. The termination of the interest rate swap was related to the repayment of the Term A-3 Facility in April 2024. Refer to Note 10, “Debt” for further information. As this interest rate swap was designated as a cash flow hedge, $ 5.5 million was deferred in accumulated other comprehensive loss (“AOCL”) and was recognized in earnings over the period the originally forecasted hedged transaction impacted earnings. The remaining $ 300 million swap was hedged against the remaining floating-rate debt through its maturity on April 3, 2025. Therefore, the Company does not have any interest rate swaps outstanding as of October 3, 2025. The cash inflows and outflows associated with the Company’s interest rate swap agreement designated as cash flow hedges were classified in cash flows from operating activities in the accompanying Consolidated and Condensed Statements of Cash Flows. 15 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) The effects of designated cash flow hedges on the Company’s Consolidated and Condensed Statements of Operations consisted of the following: Three Months Ended Nine Months Ended Derivative Type Gain Recognized in the Consolidated and Condensed Statements of Operations October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 (In thousands) Interest rate swap agreement(s) Interest expense and other, net $ — $ ( 1,910 ) $ ( 1,414 ) $ ( 7,680 ) Net Investment Hedges On July 22, 2022, the Company entered into two cross-currency swap agreements, set to mature in April 2025, to partially hedge its net investment in its Euro-denominated subsidiaries against adverse movements in exchange rates between the U.S. Dollar and the Euro. The cross-currency swap agreements included provisions to exchange fixed-rate payments in U.S. Dollar for fixed-rate payments in Euro and were designated and qualified as a net investment hedge. These contracts had a Euro aggregate notional amount of approximately € 270 million and a U.S. Dollar aggregate notional amount of $ 275 million. Prior to the maturity of these two cross-currency swaps, on June 25, 2024, the Company de-designated these swaps and entered into four new cross-currency swaps for the same above notional amounts that mature in October 2026. On August 22, 2024, the Company entered into two additional cross-currency swap agreements, set to mature in October 2026. These contracts have a Euro aggregate notional amount of approximately € 90 million and a U.S. dollar aggregate notional amount of $ 100 million. These swaps are designated and accounted for as a net investment hedge. The changes in the spot rate of these instruments are recorded in AOCI in equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in AOCI. The Company uses the spot method of assessing hedge effectiveness and as such, the initial value of the hedge components excluded from the assessment of effectiveness is recognized in the Interest expense and other, net line item in the Consolidated and Condensed Statements of Operations under a systematic and rational method over the life of the cross-currency swap agreements. Any ineffective portions of net investment hedges are reclassified from AOCI into earnings during the period of change. Due to the de-designation transaction above on June 25, 2024, the Company will keep the balance in AOCI related to the original derivative for the duration that the investment is held. The Company did not have any ineffectiveness related to net investment hedges during the nine months ended October 3, 2025. The cash inflows and outflows associated with the excluded components of the Company’s cross-currency swap agreements designated as net investment hedges are classified in operating activities in the accompanying Consolidated and Condensed Statements of Cash Flows. The effects of the excluded components of designated net investment hedges on the Company’s Consolidated and Condensed Statements of Operations consisted of the following: Three Months Ended Nine Months Ended Derivative Type Gain Recognized in the Consolidated and Condensed Statements of Operations October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 (In thousands) Cross-currency swap agreements Interest expense and other, net $ ( 903 ) $ ( 1,061 ) $ ( 1,687 ) $ ( 3,415 ) The table below shows the fair value of the derivatives recognized in the Consolidated and Condensed Balance Sheets: October 3, 2025 December 31, 2024 Designated as Hedging Instruments Other Liabilities Other Assets Other Liabilities Other Assets (In thousands) Cross-currency swap agreements $ 49,741 $ — $ 1,830 $ — Interest rate swap agreement — — — 842 $ 49,741 $ — $ 1,830 $ 842 16 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) Derivatives Not Designated as Hedging Instruments The Company has certain foreign currency contracts that are not designated as hedges. As of October 3, 2025 and December 31, 2024, the Company had foreign currency contracts related to purchases and sales with notional values of $ 130.2 million and $ 178.7 million, respectively. The table below shows the fair value of derivative instruments not designated in a hedging relationship recognized in the Consolidated and Condensed Balance Sheets: October 3, 2025 December 31, 2024 Not Designated as Hedging Instruments Accrued Liabilities Other Current Assets Accrued Liabilities Other Current Assets (In thousands) Foreign currency contracts $ 387 $ 2,209 $ 379 $ 255 The amounts in the table above as of October 3, 2025 reflect the fair value of the Company’s foreign currency contracts on a net basis where allowable under master netting agreements. Had these amounts been recognized on a gross basis, the impact would have been a $ 0.4 million increase in Other current assets with a corresponding increase in Accrued liabilities. The Company recognized the following in its Consolidated and Condensed Financial Statements related to its derivative instruments not designated in a hedging relationship: Three Months Ended Nine Months Ended Foreign Currency Contracts October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 (In thousands) Change in unrealized gains (losses) $ 660 $ ( 1,220 ) $ 1,945 $ ( 591 ) Realized gains $ 670 $ 919 $ 2,260 $ 903 The above gains or losses on foreign currency contracts are usually offset by foreign exchange exposure on cash and intercompany positions, all of which are recognized in Interest expense and other, net, in the Consolidated and Condensed Statements of Operations. 12. Financial Instruments and Fair Value Measurements The carrying values of financial instruments, including Trade receivables and Accounts payable, approximate their fair values due to their short-term maturities. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. A summary of the Company’s assets and liabilities that are measured at fair value for each fair value hierarchy level for the periods presented is as follows: October 3, 2025 December 31, 2024 Level One Level Two Level Three Total Level One Level Two Level Three Total (In thousands) Assets: Cash equivalents $ 14,997 $ — $ — $ 14,997 $ 8,990 $ — $ — $ 8,990 Foreign currency contracts — 2,614 — 2,614 — 657 — 657 Interest rate swap agreement — — — — — 842 — 842 Deferred compensation plans — 6,895 — 6,895 — 5,242 — 5,242 $ 14,997 $ 9,509 $ — $ 24,506 $ 8,990 $ 6,741 $ — $ 15,731 Liabilities: Foreign currency contracts $ — $ 792 $ — $ 792 $ — $ 781 $ — $ 781 Cross-currency swap agreements — 49,741 — 49,741 — 1,830 — 1,830 Deferred compensation plans — 6,895 — 6,895 — 5,242 — 5,242 $ — $ 57,428 $ — $ 57,428 $ — $ 7,853 $ — $ 7,853 17 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) The Company measures the fair value of foreign currency contracts, cross-currency swap agreements and interest rate swap agreement(s) using Level Two inputs based on observable spot and forward rates in active markets. Additionally, the fair value of derivatives designated in hedging relationships includes a credit valuation adjustment to appropriately incorporate nonperformance risk for the Company and the respective counterparty. For the nine months ended October 3, 2025, the impact of the credit valuation adjustment on the Company’s derivatives is immaterial. Refer to Note 11, “Derivatives” for additional information. There were no transfers in or out of Level One, Two or Three during the nine months ended October 3, 2025. 18 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) 13. Equity Share Repurchase Program On August 13, 2024, the Board of Directors authorized and approved a stock repurchase program to repurchase up to five million shares of the Company’s Common stock, par value $ 0.001 per share, from time-to-time on the open market, in privately negotiated transactions or as may otherwise be determined by the Company’s management in its discretion. No repurchases of the Company’s Common stock have been made through the nine months ended October 3, 2025. The timing and amount of any shares repurchased will be determined by the Company’s management based on its evaluation of market conditions, applicable legal requirements and other factors. There is no term associated with the repurchase authorization. Accumulated Other Comprehensive Loss The following tables present the changes in the balances of each component of AOCL including reclassifications out of AOCL for the nine months ended October 3, 2025 and September 27, 2024. All amounts are net of tax and noncontrolling interest, if any. 19 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) Accumulated Other Comprehensive Loss Components Net Unrecognized Pension and Other Post-Retirement Benefit Cost Foreign Currency Translation Adjustment Net Investment Hedges Cash Flow Hedges Total (In thousands) Balance at December 31, 2024 $ ( 50,352 ) $ ( 679,791 ) $ ( 1,247 ) $ 1,816 $ ( 729,574 ) Other comprehensive (loss) income before reclassifications: Net actuarial loss 48 — — — 48 Foreign currency translation adjustment ( 421 ) 94,613 ( 15,371 ) — 78,821 Gain on long-term intra-entity foreign currency transactions — 391 — — 391 Unrealized gain on cash flow hedges — — — 16 16 Other comprehensive (loss) income before reclassifications ( 373 ) 95,004 ( 15,371 ) 16 79,276 Amounts reclassified from Accumulated other comprehensive loss (1)(2) 273 — — ( 1,832 ) ( 1,559 ) Net current period Other comprehensive (loss) income ( 100 ) 95,004 ( 15,371 ) ( 1,816 ) 77,717 Balance at April 4, 2025 ( 50,452 ) ( 584,787 ) ( 16,618 ) — ( 651,857 ) Other comprehensive (loss) income before reclassifications: Foreign currency translation adjustment ( 431 ) 117,446 ( 25,027 ) — 91,988 Gain on long-term intra-entity foreign currency transactions — 9,968 — — 9,968 Other comprehensive (loss) income before reclassifications ( 431 ) 127,414 ( 25,027 ) — 101,956 Amounts reclassified from Accumulated other comprehensive loss (1) 202 — — — 202 Net current period Other comprehensive (loss) income ( 229 ) 127,414 ( 25,027 ) — 102,158 Balance at July 4, 2025 ( 50,681 ) ( 457,373 ) ( 41,645 ) — ( 549,699 ) Other comprehensive (loss) income before reclassifications: Foreign currency translation adjustment ( 56 ) ( 7,176 ) 3,244 — ( 3,988 ) Loss on long-term intra-entity foreign currency transactions — ( 773 ) — — ( 773 ) Other comprehensive (loss) income before reclassifications ( 56 ) ( 7,949 ) 3,244 — ( 4,761 ) Amounts reclassified from Accumulated other comprehensive loss (1) 250 — — — 250 Net current period Other comprehensive (loss) income 194 ( 7,949 ) 3,244 — ( 4,511 ) Balance at October 3, 2025 $ ( 50,487 ) $ ( 465,322 ) $ ( 38,401 ) $ — $ ( 554,210 ) (1) The amounts on this line within the Net Unrecognized Pension and Other Post-Retirement Benefit Cost column are included in the computation of net periodic benefit cost. (2) The amount within the Cash Flow Hedges column is a component of Interest expense and other, net. See Note 11, “Derivatives” for additional details. 20 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) Accumulated Other Comprehensive Loss Components Net Unrecognized Pension and Other Post-Retirement Benefit Cost Foreign Currency Translation Adjustment Net Investment Hedges Cash Flow Hedges Total (In thousands) Balance at December 31, 2023 $ ( 59,805 ) $ ( 554,622 ) $ ( 17,215 ) $ 7,370 $ ( 624,272 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 243 ( 38,265 ) 4,995 — ( 33,027 ) Gain on long-term intra-entity foreign currency transactions — 7,996 — — 7,996 Unrealized gain on cash flow hedges — — — 3,920 3,920 Other comprehensive income (loss) before reclassifications 243 ( 30,269 ) 4,995 3,920 ( 21,111 ) Amounts reclassified from Accumulated other comprehensive loss (1)(2) 629 — — ( 2,907 ) ( 2,278 ) Net current period Other comprehensive income (loss) 872 ( 30,269 ) 4,995 1,013 ( 23,389 ) Balance at March 29, 2024 ( 58,933 ) ( 584,891 ) ( 12,220 ) 8,383 ( 647,661 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 6 ( 23,042 ) 686 — ( 22,350 ) Gain on long-term intra-entity foreign currency transactions — 8,162 — — 8,162 Unrealized gain on cash flow hedges — — — 811 811 Other comprehensive income (loss) before reclassifications 6 ( 14,880 ) 686 811 ( 13,377 ) Amounts reclassified from Accumulated other comprehensive loss (1)(2) 327 — — ( 2,662 ) ( 2,335 ) Net current period Other comprehensive income (loss) 333 ( 14,880 ) 686 ( 1,851 ) ( 15,712 ) Balance at June 28, 2024 ( 58,600 ) ( 599,771 ) ( 11,534 ) 6,532 ( 663,373 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment ( 291 ) 63,336 ( 8,945 ) — 54,100 Gain on long-term intra-entity foreign currency transactions — 8,866 — — 8,866 Unrealized loss on cash flow hedges — — — ( 1,230 ) ( 1,230 ) Other comprehensive income (loss) before reclassifications ( 291 ) 72,202 ( 8,945 ) ( 1,230 ) 61,736 Amounts reclassified from Accumulated other comprehensive loss (1)(2) 343 — — ( 1,900 ) ( 1,557 ) Purchase related to noncontrolling interest — ( 1,706 ) — — ( 1,706 ) Net current period Other comprehensive income (loss) 52 70,496 ( 8,945 ) ( 3,130 ) 58,473 Balance at September 27, 2024 $ ( 58,548 ) $ ( 529,275 ) $ ( 20,479 ) $ 3,402 $ ( 604,900 ) (1) The amounts on this line within the Net Unrecognized Pension and Other Post-Retirement Benefit Cost column are included in the computation of net periodic benefit cost. (2) The amount within the Cash Flow Hedges column is a component of Interest expense and other, net. See Note 11, “Derivatives” for additional details. 21 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) 14. Commitments and Contingencies Asbestos Contingencies Certain entities are the legal obligor, or owner, for certain asbestos obligations including long-term asbestos insurance assets, long-term asbestos insurance receivables, accrued asbestos liabilities, long-term asbestos liabilities, asbestos indemnity expenses, asbestos-related defense costs and asbestos insurance recoveries related to the asbestos obligations of the Company’s legacy industrial businesses. As a result, the Company holds certain asbestos-related contingencies and insurance coverages. These subsidiaries are each one of many defendants in a large number of lawsuits that claim personal injury as a result of exposure to asbestos from products manufactured or used with components that are alleged to have contained asbestos. Such components were acquired from third-party suppliers, and were not manufactured by any of the Company’s subsidiaries, nor were the subsidiaries producers or direct suppliers of asbestos. The manufactured products that are alleged to have contained or used asbestos generally were provided to meet the specifications of the subsidiaries’ customers, including the U.S. Navy. The subsidiaries settle asbestos claims for amounts the Company considers reasonable given the facts and circumstances of each claim. The annual average settlement payment per asbestos claimant has fluctuated during the past several years while the number of cases has remained substantially even versus prior year. The Company expects such settlement value fluctuations to continue in the future based upon, among other things, the number and type of claims settled in a particular period and the jurisdictions in which such claims arise. To date, the majority of settled claims have been dismissed for no payment to plaintiffs. The Company has classified asbestos-related activity in Loss from discontinued operations, net of taxes in the Consolidated and Condensed Statements of Operations. Refer to the 2024 Form 10-K for further detail on this classification. The Company has projected each subsidiary’s future asbestos-related liability costs with regard to pending and future unasserted claims based upon the Nicholson methodology. The Nicholson methodology is a standard approach used by experts and has been accepted by numerous courts. It is ESAB’s policy to record a liability for asbestos-related liability costs for the longest period of time that ESAB management can reasonably estimate. The Company believes that it can reasonably estimate the asbestos-related liability for pending and future claims that will be resolved in the next 15 years and has recorded that liability at its best estimate. While it is reasonably possible that the subsidiaries will incur costs after this period, the Company does not believe the reasonably possible loss or a range of reasonably possible losses is estimable at the current time. Accordingly, no accrual has been recorded for any costs that may be paid after the next 15 years. Defense costs associated with asbestos-related liabilities as well as costs incurred related to efforts to recover insurance from the subsidiaries’ insurers are expensed as incurred. Each subsidiary has separate insurance coverage that was acquired prior to Company ownership. The Company estimates the insurance assets for each subsidiary based upon the applicable policy language, expected recoveries and allocation methodologies, and law pertaining to the affected subsidiary’s insurance policies. Asbestos-related claims activity since December 31 is as follows: Nine Months Ended October 3, 2025 September 27, 2024 (Number of claims) Claims unresolved, beginning of period 13,758 13,648 Claims filed (1) 3,814 3,782 Claims resolved (2) ( 3,415 ) ( 3,978 ) Claims unresolved, end of period 14,157 13,452 (1) Claims filed include all asbestos claims for which notification has been received or a file has been opened. (2) Claims resolved include all asbestos claims that have been settled, dismissed or that are in the process of being settled or dismissed based upon agreements or understandings in place with counsel for the claimants. 22 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) The Company’s Consolidated and Condensed Balance Sheets included the following amounts related to asbestos-related litigation: October 3, 2025 December 31, 2024 (In thousands) Long-term asbestos insurance asset (1) $ 257,020 $ 234,951 Long-term asbestos insurance receivable (1) 17,626 16,961 Accrued asbestos liability (2) 43,335 40,779 Long-term asbestos liability (3) $ 279,473 $ 253,287 (1) Included in Other assets in the Consolidated and Condensed Balance Sheets. (2) Represents current accruals for probable and reasonably estimable asbestos-related liability costs that the Company believes the subsidiaries will pay and unpaid legal costs related to defending themselves against asbestos-related liability claims and legal action against the Company’s insurers, which is included in Accrued liabilities in the Consolidated and Condensed Balance Sheets. (3) Included in Other liabilities in the Consolidated and Condensed Balance Sheets. Management’s analyses are based on currently known facts and assumptions. Projecting future events, such as new claims to be filed each year, the average cost of resolving each claim, coverage issues among layers of insurers, the method in which losses will be allocated to the various insurance policies, interpretation of the effect on coverage of various policy terms and limits and their interrelationships, the continuing solvency of various insurance companies, the amount of remaining insurance available, as well as the numerous uncertainties inherent in asbestos litigation could cause the actual liabilities and insurance recoveries to be higher or lower than those projected or recorded that could materially affect the Company’s financial condition, results of operations or cash flow. From time to time, other asbestos allegations related to the Company’s legacy industrial businesses are brought against the Company. Management currently believes no loss is probable or estimable for these other matters. General Litigation The Company is involved in various pending legal proceedings arising out of the ordinary course of the Company’s business. None of these legal proceedings are expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings, and the litigation and claims described in the preceding paragraphs, management of the Company believes that it will either prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Legal costs related to proceedings or claims are recorded when incurred. Other costs that management estimates may be paid related to the claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these legal proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company. 15. Segment Information ESAB is a focused premier industrial compounder. ESAB provides its partners with fabrication technology advanced equipment, consumables, gas control equipment, welding robotics and digital solutions. The Company conducts its operations through two reportable segments. These segments consist of the “Americas,” which includes operations in North America and South America, and “EMEA & APAC,” which includes Europe, Middle East, India, Africa and Asia Pacific. The Company’s management considers its Chief Operating Decision Maker (“CODM”) as Shyam Kambeyanda, President, Chief Executive Officer and Director. The Company’s management and CODM evaluate the operating results of each reportable segment, including assessment of profit or loss, performance and allocation of resources, based upon Net sales and Adjusted EBITDA, which represents Net income from continuing operations excluding the impact of Income tax expense, Interest expense and other, net, Pension settlement loss, Restructuring and other related charges, acquisition - amortization and other related charges and depreciation and other amortization . Segment results reflect the allocation of overhead costs, which primarily consist of Selling, general and administrative expense. 23 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) The Com pany’s segment results were as follows: Three Months Ended Nine Months Ended October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 (In thousands) Net sales: Americas $ 292,729 $ 288,816 $ 856,123 $ 894,628 EMEA & APAC 435,116 384,434 1,265,446 1,175,419 $ 727,845 $ 673,250 $ 2,121,569 $ 2,070,047 Cost of sales: Americas $ 180,572 $ 174,396 $ 522,738 $ 546,287 EMEA & APAC 277,973 245,064 808,282 744,628 $ 458,545 $ 419,460 $ 1,331,020 $ 1,290,915 Allocated operating expense: Americas $ 13,878 $ 16,901 $ 41,395 $ 50,620 EMEA & APAC 23,256 25,835 74,415 76,514 $ 37,134 $ 42,736 $ 115,810 $ 127,134 Other operating expense: Americas $ 41,024 $ 38,150 $ 123,452 $ 119,570 EMEA & APAC 51,644 45,469 134,392 134,883 $ 92,668 $ 83,619 $ 257,844 $ 254,453 Adjusted EBITDA (1) : Americas $ 57,255 $ 59,369 $ 168,538 $ 178,151 EMEA & APAC 82,243 68,066 248,357 219,394 $ 139,498 $ 127,435 $ 416,895 $ 397,545 Depreciation, amortization and other impairment charges: Americas $ 8,998 $ 7,704 $ 25,846 $ 23,208 EMEA & APAC 12,887 9,394 32,885 26,820 $ 21,885 $ 17,098 $ 58,731 $ 50,028 Capital expenditures: Americas $ 4,218 $ 5,516 $ 12,334 $ 11,745 EMEA & APAC 6,962 5,118 15,320 15,326 $ 11,180 $ 10,634 $ 27,654 $ 27,071 (1) The following is a reconciliation of Net income from continuing operations to Adjusted EBITDA. Three Months Ended Nine Months Ended October 3, 2025 September 27, 2024 October 3, 2025 September 27, 2024 (In thousands) Net income from continuing operations $ 65,340 $ 71,047 $ 207,716 $ 219,480 Income tax expense 17,694 18,074 56,476 54,463 Interest expense and other, net 23,584 16,894 61,365 49,925 Pension settlement loss — — — 12,155 Restructuring and other related charges (1) 4,347 1,875 10,236 8,572 Acquisition - amortization and other related charges (2) 16,489 10,064 47,682 25,571 Depreciation and other amortization 12,044 9,481 33,420 27,379 Adjusted EBITDA $ 139,498 $ 127,435 $ 416,895 $ 397,545 24 ESAB CORPORATION NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued) (Unaudited) (1) I ncludes severance and other termination benefits, including outplacement services, as well as the cost of relocating associates, relocating equipment, lease termination expenses, impairment of long-lived assets and other costs in connection with the closure and optimization of facilities and product lines . (2) Includes transaction, diligence and integration expenses totaling $ 6.1 million and $ 20.4 million for the three and nine months ended October 3, 2025, respectively, and $ 2.5 million and $ 3.1 million for the three and nine months ended September 27, 2024, respectively. Additionally, it includes amortization of intangibles and fair value charges on acquired inventories totaling $ 10.3 million and $ 27.3 million three and nine months ended October 3, 2025, respectively, and $ 7.6 million and $ 22.4 million for the three and nine months ended September 27, 2024, respectively. October 3, 2025 December 31, 2024 (In thousands) Investments in equity method investees: Americas $ — $ — EMEA & APAC 31,372 28,885 $ 31,372 $ 28,885 Total assets: Americas $ 1,833,862 $ 1,796,167 EMEA & APAC 3,035,541 2,237,808 $ 4,869,403 $ 4,033,975 Property, plant and equipment, net (1) : United States $ 72,276 $ 73,036 Czech Republic 71,784 55,554 India 31,714 31,506 Mexico 23,081 20,495 Poland 19,731 17,227 Other foreign countries 139,341 100,529 $ 357,927 $ 298,347 (1) As the Company does not allocate all long-lived assets, specifically intangible assets, to each individual country, evaluation of long-lived assets in total is impracticable. 16. Subsequent Events The dividend of $ 6.1 million included in Accrued liabilities in the Consolidated and Condensed Balance Sheets at October 3, 2025 was paid on October 17, 2025 to stockholders of record as of October 3, 2025. On October 16, 2025, the Company entered into an Amended and Restated Credit Agreement, by and among the Company, as the lead borrower, the other loan parties from time to time party thereto, including certain subsidiaries of the Company identified therein, as guarantors, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent (the “A&R Credit Agreement”). The A&R Credit Agreement, among other things, provides for (i) a senior term loan A facility in an aggregate principal amount of $ 350 million, and (ii) a senior revolving credit facility in the amount of $ 1.05 billion to pay off the outstanding principal and interest on the Company’s existing $ 400 million Term Loan A-1 Facility and replace the Company’s $ 750 million Revolving Facility. Both facilities mature on October 16, 2030, subject to a springing maturity date under certain circumstances. 25